The Psychedelic Moon Landing: Inside the World's First Legal Extended-State DMT Research Center

What does it look like when a decade of ketamine therapy experience, a government-issued psychedelic research license in the Caribbean, and the world's most advanced DMT infusion protocol converge in a single clinical operation? On this episode of Inside the Revival, host Jim Tate engages Charles Patti, co-founder and Chief Visionary Officer of Eleusis Mind, operating in Saint Vincent and the Grenadines, to explore extended-state DMT (DMTx) research as it is actually being practiced, not theorized. Patti traces the scientific lineage of DMTx from Dr. Rick Strassman's DEA-approved human trials at the University of New Mexico in the 1990s through Dr. Andrew Gallimore and Dr. Chris Timmermann's landmark pilot study at Imperial College London, and into Eleusis Mind's applied research protocol, i.e., 150-plus sessions to date, with 78% of participants reporting entity contact experiences. He details the center's tiered immersion programs (4-day/3-night Essential and 6-day/5-night Complete), its rigorous screening infrastructure, its SSRI and contraindication protocols, and its use of AI-assisted journey report analysis to map the DMT state. He also locates DMTx within the fast-evolving U.S. regulatory landscape, including President Trump's April 2026 executive order directing $50 million toward psychedelic research and makes the case for DMT and ketamine as the molecules most suited to scalable clinical application.